New study aims to tame harsh side effects of aplastic anemia therapy
NCT ID NCT07461116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study watches 200 people with aplastic anemia who are getting ATG/ALG treatment for the first time. Researchers will track side effects like serum sickness, organ damage, and infusion reactions to learn how common and severe they are. The goal is to create better guidelines for managing these reactions and improving patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Regenerative Medicine Center and Red Blood Cell Disorders Center
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for older adults with rare blood disorder: safer transplant regimen under study
- New combo therapy for rare blood disorder shows promise
- Double stem cell transplant could be Game-Changer for rare blood disorder
- New study: which first treatment works best for severe aplastic anemia?
- New transplant recipe may tame severe anemia